Tao Yuan, Sun Mingyang, Miao Mengrong, Han Yaqian, Yang Yitian, Cong Xuhui, Zhang Jiaqiang
Department of Anesthesiology and Perioperative Medicine, Zhengzhou University People's Hospital, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
Front Surg. 2022 Aug 15;9:949614. doi: 10.3389/fsurg.2022.949614. eCollection 2022.
High flow nasal cannula is gaining increasingly used in patients undergoing endoscopic procedures. We undertook this systematic review and meta-analysis to determine whether high flow nasal cannula (HFNC) could effectively minimize the risk of hypoxemia as compared with conventional oxygen therapy (COT).
We performed a comprehensive search of Pubmed, Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and Web of Science. Studies involving the application of HFNC during endoscopic procedures were identified.
We included 15 randomized controlled trials (7 bronchoscopy, 8 gastrointestinal endoscopy). Patients receiving HFNC during endoscopic procedures had a significantly lower risk of hypoxemia (defined as SpO < 90%) versus COT group (risk ratio = 0.32; 95%CI (0.22-0.47), 13 studies, 4,093 patients, moderate-quality evidence, = 48.82%, < 0.001). The lowest SpO was significantly higher in HFNC group (mean difference = 4.41; 95%CI (2.95-5.86), 9 studies, 1,449 patients, moderate-quality evidence, = 81.17%, < 0.001) than those receiving COT. No significant difference was detected between groups in end-procedure partial pressure of CO (standard mean difference = -0.18; 95%CI (-0.52-0.15), 5 studies, 238 patients, moderate-quality evidence, = 42.25%, = 0.29). Patients receiving HFNC were associated a lower need for airway intervention (risk ratio = 0.45; 95%CI (0.24-0.84), 8 studies, 2,872 patients, moderate-quality evidence, = 85.97%, = 0.01) and less procedure interruption (risk ratio = 0.36; 95%CI (0.26-0.51), 6 studies, 1,562 patients, moderate-quality evidence, = 0.00%, < 0.001). The overall intubation rate after endoscopy was 0.20% in both group, with no difference detected (risk ratio = 1.00; 95%CI (0.30-3.35), 7 studies, 2,943 patients, low-quality evidence, = 0.00%, = 1.00).
This systematic review and meta-analysis found moderate to low evidence that the application of HFNC was associated with improved oxygenation, decreased need for airway intervention, and reduced procedure interruption in patients undergoing endoscopic procedures. Future larger sample and high-quality studies are warranted to confirm our result and further investigate the effectiveness of HFNC in patients at risk. : https://www.crd.york.ac.uk/prospero/, identifier: CRD42022298032.
高流量鼻导管吸氧在接受内镜检查的患者中越来越常用。我们进行了这项系统评价和荟萃分析,以确定与传统氧疗(COT)相比,高流量鼻导管吸氧(HFNC)是否能有效降低低氧血症风险。
我们全面检索了PubMed、Cochrane对照试验中心注册库(CENTRAL)、Embase和科学网。纳入了在内镜检查期间应用HFNC的研究。
我们纳入了15项随机对照试验(7项支气管镜检查,8项胃肠镜检查)。与COT组相比,在内镜检查期间接受HFNC的患者发生低氧血症(定义为SpO<90%)的风险显著降低(风险比=0.32;95%CI(0.22-0.47),13项研究,4093例患者,中等质量证据,I²=48.82%,P<0.001)。HFNC组的最低SpO显著高于接受COT的患者(平均差值=4.41;95%CI(2.95-5.86),9项研究,1449例患者,中等质量证据,I²=81.17%,P<0.001)。两组在检查结束时的二氧化碳分压方面未检测到显著差异(标准平均差值=-0.18;95%CI(-0.52-0.15),5项研究,238例患者,中等质量证据,I²=42.25%,P=0.29)。接受HFNC的患者气道干预需求较低(风险比=0.45;95%CI(0.24-0.84),8项研究,2872例患者,中等质量证据,I²=85.97%,P=0.01),检查中断较少(风险比=0.36;95%CI(0.26-0.51),6项研究,1562例患者,中等质量证据,I²=0.00%,P<0.001)。两组内镜检查后的总体插管率均为0.20%,未检测到差异(风险比=1.00;95%CI(0.30-3.35),7项研究,2943例患者,低质量证据,I²=0.00%,P=1.00)。
这项系统评价和荟萃分析发现,有中等至低质量证据表明,应用HFNC与改善接受内镜检查患者的氧合、降低气道干预需求及减少检查中断有关。未来需要更大样本量和高质量的研究来证实我们的结果,并进一步研究HFNC对高危患者的有效性。:https://www.crd.york.ac.uk/prospero/,标识符:CRD42022298032